Skip to Content

Arepanrix

Active Substance: split influenza virus, inactivated, containing antigen* : A/California/7/2009 (H1N1)v like strain (X-179A) * produced in eggs
Common Name: pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)
ATC Code: J07BB02
Marketing Authorisation Holder: GlaxoSmithKline Biologicals S.A.
Active Substance: split influenza virus, inactivated, containing antigen* : A/California/7/2009 (H1N1)v like strain (X-179A) * produced in eggs
Status: Withdrawn
Authorisation Date: 2010-03-23
Therapeutic Area: Influenza, Human Immunization Disease Outbreaks
Pharmacotherapeutic Group: Influenza vaccines

Therapeutic Indication

Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance

The marketing authorisation for Arepanrix has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide